MEI Pharma (NASDAQ:MEIP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
According to Zacks, “MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. “
A number of other analysts have also recently weighed in on the company. Cann reiterated a “buy” rating and issued a $6.50 price target on shares of MEI Pharma in a research report on Monday, December 11th. Oppenheimer reiterated a “buy” rating and issued a $6.50 price target on shares of MEI Pharma in a research report on Monday, December 11th. Finally, ValuEngine cut MEI Pharma from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.
MEI Pharma (NASDAQ:MEIP) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). MEI Pharma had a negative net margin of 8.24% and a negative return on equity of 3.62%. sell-side analysts forecast that MEI Pharma will post -1.05 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its holdings in shares of MEI Pharma by 2,508.7% during the second quarter. JPMorgan Chase & Co. now owns 67,825 shares of the company’s stock worth $162,000 after purchasing an additional 65,225 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of MEI Pharma by 12.3% during the second quarter. Vanguard Group Inc. now owns 740,580 shares of the company’s stock worth $1,770,000 after purchasing an additional 81,308 shares during the last quarter. Nationwide Fund Advisors bought a new stake in shares of MEI Pharma during the third quarter worth $229,000. Macquarie Group Ltd. bought a new stake in shares of MEI Pharma during the third quarter worth $306,000. Finally, OxFORD Asset Management LLP grew its holdings in shares of MEI Pharma by 116.2% during the second quarter. OxFORD Asset Management LLP now owns 235,025 shares of the company’s stock worth $562,000 after purchasing an additional 126,303 shares during the last quarter. Institutional investors own 23.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “MEI Pharma (MEIP) Cut to “Sell” at Zacks Investment Research” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2018/01/14/mei-pharma-meip-cut-to-sell-at-zacks-investment-research.html.
MEI Pharma Company Profile
MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about MEI Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MEI Pharma and related companies.